Hosted on MSN

Scribe’s genetic editing aims to prevent heart attacks

Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can ...
Business Wire

Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Data demonstrate proprietary X-Editors engineered using Scribe’s CRISPR by Design™ approach are a promising gene editing platform for developing genetic medicines with high activity, specificity and ...
Pulse 2.0

Scribe Therapeutics Awarded Over $25 Million From CIRM For CRISPR-Based Gene Editing Programs

Scribe Therapeutics announced that it has been awarded more than $25 million from the California Institute for Regenerative Medicine across two preclinical programs targeting cardiovascular and ...
Business Wire

Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene ...

Oral presentation on novel allosteric ELXR epigenetic silencer showcases Scribe’s development in achieving highly precise, potent, and durable target repression XE gene editor oral presentation ...
GEN

Scribe Pursues CRISPR Therapies with Expanded Biogen Collaboration

Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A year and a half into a collaboration with Biogen to develop CRISPR-based therapies, Scribe Therapeutics says the companies ...
GEN

Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration

Benjamin L. Oakes, PhD, Scribe Therapeutics co-founder, president, and CEO Scribe Therapeutics will partner with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, to develop in vivo CRISPR ...